pEGASUS-HPC和CREDO Heal支架系统经NeuroSpeed经皮血管成形术球囊导管治疗急性症状性颅内狭窄和闭塞的比较

IF 2.6 3区医学 Q2 Medicine

Clinical Neuroradiology Pub Date : 2025-08-08 DOI:10.1007/s00062-025-01544-1

Abdallah Aburub, Mohammad Almohammad, Ali Khanafer, Zakarya Ali, Mariana Gurschi, Yashar Aghazadeh, Mete Dadak, Tawfik Moher Alsady, Lars Timmermann, Ole Simon, Anja Gerstner, Bayan Alhaj Moustafa, Oussama Dob, Christopher Nimsky, Benjamin Saß, Hans Henkes, André Kemmling

{"title":"pEGASUS-HPC和CREDO Heal支架系统经NeuroSpeed经皮血管成形术球囊导管治疗急性症状性颅内狭窄和闭塞的比较","authors":"Abdallah Aburub, Mohammad Almohammad, Ali Khanafer, Zakarya Ali, Mariana Gurschi, Yashar Aghazadeh, Mete Dadak, Tawfik Moher Alsady, Lars Timmermann, Ole Simon, Anja Gerstner, Bayan Alhaj Moustafa, Oussama Dob, Christopher Nimsky, Benjamin Saß, Hans Henkes, André Kemmling","doi":"10.1007/s00062-025-01544-1","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the efficacy and safety of the pEGASUS-HPC and CREDO heal coated stent systems used with the NeuroSpeed percutaneous angioplasty (PTA) balloon catheter, for treating acute symptomatic intracranial artery stenosis (ICAS) with or without acute vessel occlusion (VO).Methods: This retrospective, multicenter study included patients with ICAS between June-2021 and June-2024 treated with the NeuroSpeed PTA balloon catheter and either stent system. Clinical endpoints included National Institutes of Health Stroke Scale (NIHSS) scores and modified ranking scores (mRS), safety and efficacy endpoints included in-stent thrombosis and in-stent stenosis.Results: Sixty-nine patients were included (pEGASUS-HPC, n = 34; CREDO heal, n = 35). Both groups showed significant improvement in arterial diameter post-intervention (pEGASUS-HPC: 0.47 mm (SD 0.27 mm) to 1.69 mm (SD 0.55 mm); CREDO heal: 0.57 mm (SD 0.41 mm) to 1.89 mm (SD 0.62 mm)). Revascularization success, defined as residual stenosis < 50%, was achieved in 32/34 (93.9%) patients in the pEGASUS-HPC group and 33/35 (94.3%) in the CREDO heal group. In-stent re-stenosis occurred in 5/34 (14.7%) of patients in the pEGASUS-HPC group and 2/35 (5.7%) in the CREDO heal group and retreatment with PTA was performed in 3/34 (8.8%) and 2/35 (5.7%), respectively. Peri- or postprocedural in-stent thrombosis occurred in 3/34 (8.8%) of patients in the pEGASUS-HPC group and 2/35 (5.7%) in the CREDO heal group. At 3-6 months, the proportion of patients achieving an mRS score of 0-2 was 25/34 (73.5%) in the pEGASUS-HPC group and 28/35 (80.0%) in the CREDO heal group (p = 0.578).Conclusion: Both stent systems proved effective and safe, showing significant post-intervention arterial dilation, high revascularization rates, and similar functional outcomes (mRS 0-2 at 3-6 months), though they differed in in-stent restenosis rates.","PeriodicalId":10391,"journal":{"name":"Clinical Neuroradiology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of pEGASUS-HPC and CREDO Heal stent systems deployed via NeuroSpeed percutaneous angioplasty balloon catheter for treatment of acute symptomatic intracranial stenosis and occlusion.\",\"authors\":\"Abdallah Aburub, Mohammad Almohammad, Ali Khanafer, Zakarya Ali, Mariana Gurschi, Yashar Aghazadeh, Mete Dadak, Tawfik Moher Alsady, Lars Timmermann, Ole Simon, Anja Gerstner, Bayan Alhaj Moustafa, Oussama Dob, Christopher Nimsky, Benjamin Saß, Hans Henkes, André Kemmling\",\"doi\":\"10.1007/s00062-025-01544-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To compare the efficacy and safety of the pEGASUS-HPC and CREDO heal coated stent systems used with the NeuroSpeed percutaneous angioplasty (PTA) balloon catheter, for treating acute symptomatic intracranial artery stenosis (ICAS) with or without acute vessel occlusion (VO).Methods: This retrospective, multicenter study included patients with ICAS between June-2021 and June-2024 treated with the NeuroSpeed PTA balloon catheter and either stent system. Clinical endpoints included National Institutes of Health Stroke Scale (NIHSS) scores and modified ranking scores (mRS), safety and efficacy endpoints included in-stent thrombosis and in-stent stenosis.Results: Sixty-nine patients were included (pEGASUS-HPC, n = 34; CREDO heal, n = 35). Both groups showed significant improvement in arterial diameter post-intervention (pEGASUS-HPC: 0.47 mm (SD 0.27 mm) to 1.69 mm (SD 0.55 mm); CREDO heal: 0.57 mm (SD 0.41 mm) to 1.89 mm (SD 0.62 mm)). Revascularization success, defined as residual stenosis < 50%, was achieved in 32/34 (93.9%) patients in the pEGASUS-HPC group and 33/35 (94.3%) in the CREDO heal group. In-stent re-stenosis occurred in 5/34 (14.7%) of patients in the pEGASUS-HPC group and 2/35 (5.7%) in the CREDO heal group and retreatment with PTA was performed in 3/34 (8.8%) and 2/35 (5.7%), respectively. Peri- or postprocedural in-stent thrombosis occurred in 3/34 (8.8%) of patients in the pEGASUS-HPC group and 2/35 (5.7%) in the CREDO heal group. At 3-6 months, the proportion of patients achieving an mRS score of 0-2 was 25/34 (73.5%) in the pEGASUS-HPC group and 28/35 (80.0%) in the CREDO heal group (p = 0.578).Conclusion: Both stent systems proved effective and safe, showing significant post-intervention arterial dilation, high revascularization rates, and similar functional outcomes (mRS 0-2 at 3-6 months), though they differed in in-stent restenosis rates.\",\"PeriodicalId\":10391,\"journal\":{\"name\":\"Clinical Neuroradiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Neuroradiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00062-025-01544-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuroradiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00062-025-01544-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的：比较pEGASUS-HPC和CREDO heal涂层支架系统与NeuroSpeed经皮血管成形术（PTA）球囊导管联合治疗伴有或不伴有急性血管闭塞（VO）的急性症状性颅内动脉狭窄（ICAS）的疗效和安全性。方法：这项回顾性、多中心研究纳入了2021年6月至2024年6月期间接受NeuroSpeed PTA球囊导管和任一支架系统治疗的ICAS患者。临床终点包括美国国立卫生研究院卒中量表（NIHSS）评分和修正排名评分（mRS），安全性和有效性终点包括支架内血栓形成和支架内狭窄。结果：纳入69例患者(pEGASUS-HPC, n = 34；CREDO heal, n = 35)。两组介入后动脉直径均有显著改善(pEGASUS-HPC: 0.47 mm （SD 0.27 mm）至1.69 mm (SD 0.55 mm)；CREDO愈合：0.57 mm （SD 0.41 mm）至1.89 mm (SD 0.62 mm))。结论：两种支架系统被证明是有效和安全的，在介入后动脉扩张显著，血运重建率高，功能结果相似（3-6个月mRS 0-2），尽管它们在支架内再狭窄率上存在差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparison of pEGASUS-HPC and CREDO Heal stent systems deployed via NeuroSpeed percutaneous angioplasty balloon catheter for treatment of acute symptomatic intracranial stenosis and occlusion.

Purpose: To compare the efficacy and safety of the pEGASUS-HPC and CREDO heal coated stent systems used with the NeuroSpeed percutaneous angioplasty (PTA) balloon catheter, for treating acute symptomatic intracranial artery stenosis (ICAS) with or without acute vessel occlusion (VO).

Methods: This retrospective, multicenter study included patients with ICAS between June-2021 and June-2024 treated with the NeuroSpeed PTA balloon catheter and either stent system. Clinical endpoints included National Institutes of Health Stroke Scale (NIHSS) scores and modified ranking scores (mRS), safety and efficacy endpoints included in-stent thrombosis and in-stent stenosis.

Results: Sixty-nine patients were included (pEGASUS-HPC, n = 34; CREDO heal, n = 35). Both groups showed significant improvement in arterial diameter post-intervention (pEGASUS-HPC: 0.47 mm (SD 0.27 mm) to 1.69 mm (SD 0.55 mm); CREDO heal: 0.57 mm (SD 0.41 mm) to 1.89 mm (SD 0.62 mm)). Revascularization success, defined as residual stenosis < 50%, was achieved in 32/34 (93.9%) patients in the pEGASUS-HPC group and 33/35 (94.3%) in the CREDO heal group. In-stent re-stenosis occurred in 5/34 (14.7%) of patients in the pEGASUS-HPC group and 2/35 (5.7%) in the CREDO heal group and retreatment with PTA was performed in 3/34 (8.8%) and 2/35 (5.7%), respectively. Peri- or postprocedural in-stent thrombosis occurred in 3/34 (8.8%) of patients in the pEGASUS-HPC group and 2/35 (5.7%) in the CREDO heal group. At 3-6 months, the proportion of patients achieving an mRS score of 0-2 was 25/34 (73.5%) in the pEGASUS-HPC group and 28/35 (80.0%) in the CREDO heal group (p = 0.578).

Conclusion: Both stent systems proved effective and safe, showing significant post-intervention arterial dilation, high revascularization rates, and similar functional outcomes (mRS 0-2 at 3-6 months), though they differed in in-stent restenosis rates.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Neuroradiology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

4.90

自引率

3.60%

发文量

期刊介绍： Clinical Neuroradiology provides current information, original contributions, and reviews in the field of neuroradiology. An interdisciplinary approach is accomplished by diagnostic and therapeutic contributions related to associated subjects. The international coverage and relevance of the journal is underlined by its being the official journal of the German, Swiss, and Austrian Societies of Neuroradiology.